We are live on ! Find out more
RNTX icon

Rein Therapeutics

64 hedge funds and large institutions have $33.1M invested in Rein Therapeutics in 2026 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

10% more capital inflows, than outflows

Capital inflows: $1.81M | Capital outflows: $1.64M

7% more funds holding

Funds holding: 60 → 64 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.07% less ownership

Funds ownership: 47.75% → 47.68% (-0.07%)

Holders
64
Holders Change
+4
Holders Change %
+6.67%
% of All Funds
0.78%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
11
Increased
13
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

RNTX Hedge Fund Activity: Q3 2026 in Review

64 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2026, worth a combined $33.1M — down 22% from $42.5M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new RNTX positions and 6 closed out — a net gain of 5 holders — while 13 added to existing stakes and 10 trimmed.

The largest buyer was Voss Capital, adding an estimated $482K. The largest seller was Great Point Partners, cutting an estimated $748K.

  • 64 institutional investors held Rein Therapeutics (RNTX) as of Q3 2026, up from 60 in Q2 2026.
  • Funds reported $33.1M of Rein Therapeutics stock for Q3 2026, down 22% quarter-over-quarter.
  • 11 funds opened new Rein Therapeutics positions in Q3 2026 and 6 closed out, a net change of +5 holders.
  • The largest Rein Therapeutics buyer in Q3 2026 was Voss Capital, an estimated $482K added.
  • The largest Rein Therapeutics seller in Q3 2026 was Great Point Partners, an estimated $748K sold.

Based on aggregated 13F filings for Q3 2026.